Alterity Therapeutics Limited, a biotechnology company operating within the health care sector, is headquartered in Melbourne, Australia. The company is primarily engaged in the research and development of therapeutic drugs aimed at treating Alzheimer’s diseases and age-related disorders. As a key player in the biotechnology industry, Alterity Therapeutics focuses on providing innovative solutions for patients residing in Australia.
The company is publicly traded on the ASX All Markets stock exchange, with its financial activities denominated in Australian Dollars (AUD). As of April 23, 2026, the close price of Alterity Therapeutics’ stock was recorded at 0.01 AUD. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of 0.0175 AUD on July 27, 2025, and a 52-week low of 0.007 AUD on March 26, 2026. The market capitalization of the company stands at 97,880,000 AUD, reflecting its valuation in the market.
Despite its focus on innovative drug development, Alterity Therapeutics has faced financial challenges, as indicated by its price-to-earnings ratio of -6.45. This negative ratio suggests that the company is currently not generating profits, which is not uncommon for companies in the biotechnology sector that are heavily invested in research and development.
Alterity Therapeutics’ commitment to addressing Alzheimer’s and age-related disorders underscores its role in advancing medical treatments within the health care sector. The company’s efforts are directed towards developing therapies that can significantly improve the quality of life for patients affected by these conditions.
For more detailed information about Alterity Therapeutics’ activities, research initiatives, and corporate updates, stakeholders and interested parties are encouraged to visit their official website at www.alteritytherapeutics.com . This platform provides comprehensive insights into the company’s strategic direction and ongoing projects in the biotechnology landscape.
